Evidence map›Paper›PMID 37410102›Full record

ArticleWorld journal of urology2023

Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer.

Pierre-Louis Reignier, Hélène Gauthier, Christophe Hennequin, Quiterie Aussedat, Evanguelos Xylinas, François Desgrandchamps, Stéphane Culine, Alexandra Masson-Lecomte, Clément Dumont

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07043543 (Randomized Open Phase II Multienter Study Evaluating the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07043543 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Randomized Open Phase II Multienter Study Evaluating the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer

TypeinterventionalSponsorInstitut du Cancer de Montpellier - Val d'AurelleRan2026 to 2033Enrolled120ConditionsBladder CancerArmsAdaptive radiotherapy, standard radiotherapy
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. The effect of incidental dose to pelvic nodes in bladder-only irradiation in the era of IMRT: a dosimetric study.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Pierre-Louis ReignierUrology Department, Saint-Louis Hospital, AP-HP.Nord Université Paris Cité, Paris, France.ORCID http://orcid.org/0000-0002-4237-4831
Hélène GauthierMedical Oncology Department, Saint-Louis Hospital, AP-HP.Nord Université Paris Cité, Paris, France.
Christophe HennequinRadiotherapy Department, Saint-Louis Hospital, AP-HP.Nord Université Paris Cité, Paris, France.
Quiterie AussedatMedical Oncology Department, Saint-Louis Hospital, AP-HP.Nord Université Paris Cité, Paris, France.
Evanguelos XylinasUrology Department, Bichat-Claude Bernard Hospital, AP-HP.Nord Université Paris Cité, Paris, France.
François DesgrandchampsUrology Department, Saint-Louis Hospital, AP-HP.Nord Université Paris Cité, Paris, France.
Stéphane CulineMedical Oncology Department, Saint-Louis Hospital, AP-HP.Nord Université Paris Cité, Paris, France.
Alexandra Masson-LecomteUrology Department, Saint-Louis Hospital, AP-HP.Nord Université Paris Cité, Paris, France.
Clément DumontMedical Oncology Department, Saint-Louis Hospital, AP-HP.Nord Université Paris Cité, Paris, France. clement.dumont@aphp.fr.
Université Paris Cité · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeto assess the respective outcomes of patients with localized muscle-invasive bladder cancer (MIBC) treated by either radical cystectomy (RC) or trimodal treatment (TMT) depending on pathological response to previous neoadjuvant chemotherapy (NAC) assessed on cystectomy specimen or post-NAC transurethral resection (TURB) specimen, respectively. PATIENT AND

methodsWe retrospectively included all consecutive patients treated in one academic center with cisplatin-based NAC followed by RC or TMT for cT2-3N0M0 MIBC between 2014 and 2021. Primary endpoint was metastasis-free survival (MFS) in both treatment groups and according to pathological response to NAC. Local recurrence-free survival and conservative management failure (metastasis-free bladder-intact survival) for patients treated with TMT were assessed.

results104 patients were included, 26 treated with TMT and 78 with RC. The rate of complete pathological response was 47.4% in patients treated with RC (ypT0) and 66.7% in patients treated with TMT (ycT0). Median follow-up was 34.9 months. Four-year MFS was 72% in both treatment groups. Four-year MFS was 85% in both ypT0 RC patients and ycT0 TMT patients. ycT0 stage was associated with low rates of intravesical recurrence and conservative management failure.

conclusionPatients with post-NAC ycT0 stage treated with TMT have favorable oncological outcomes similar to those of ypT0 patients treated with RC. Assessment of complete histological response with TURB after NAC may help in selecting the best candidates for bladder preservation with TMT.

Indexed as

Urinary BladderUrinary Bladder NeoplasmsCystectomyHumansMusclesNeoadjuvant TherapyNeoplasm InvasivenessRetrospective StudiesMuscle invasive bladder cancerNeoadjuvant chemotherapyRadiotherapySurvival

Identifiers

PMID37410102
OpenAlexW4383301720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.